Business Wire

H2SITE

29.4.2024 08:31:28 CEST | Business Wire | Press release

Share
H2SITE’s AMMONIA to H2POWER Technology Receives Approval in Principle From Lloyd’s Register

Ammonia cracking is gaining momentum as a potential hydrogen carrier for onboard applications and this system is based on H2SITE’s hydrogen-selective membranes that overcome the thermodynamic limitations of the ammonia cracking reaction by recovering hydrogen continuously and resulting in virtually complete ammonia conversion and higher efficiencies at lower temperatures, reducing overall energy consumption and footprint.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428422597/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

In awarding the AIP, the design and arrangement evaluation included an overall examination of fundamental aspects of the design and compliance with LR’s Rules and Regulations for the Classification of Ships using Gases or other Low-flashpoint Fuels. A preliminary appraisal of rules was undertaken, followed by a risk assessment conducted to ensure that the risks arising from the use of ammonia and hydrogen are addressed according to LR’s ShipRight Procedure for Risk-Based Certification (RBC).

H2SITE operationally demonstrated its ammonia to hydrogen power technology last November when the Zumaia Offshore’s Bertha B vessel carried onboard AMMONIA to H2POWER technology, validating its performance in actual offshore conditions.

"We are proud to have achieved this milestone, as it validates the design and safety of our onboard ammonia cracking technology for decarbonizing maritime applications based on membrane reactors. Having commissioned our first cracker and fuel cell unit last year aboard the supply vessel Bertha B, we are currently scaling up the technology and designing MW-scale units." according to Jose Medrano Technical Director at H2SITE.

These AMMONIA to H2POWER systems will be integrated with both propulsion systems and auxiliary power units to serve a range of vessels, from offshore platforms to tankers and gas carriers.

Mark Darley, Chief Operations Officer, Lloyd’s Register added: “H2SITE's AMMONIA to H2POWER technology represents an exciting opportunity for shipowners to convert ammonia, and other feedstocks such as methanol, to hydrogen onboard their vessels without using additional gas separation technology”.

“We are pleased to award the AiP for this novel solution, and we remain dedicated to working with the maritime value chain to provide zero-emission power solutions that can contribute towards a greener, more sustainable future.”

About H2SITE

H2SITE was created in 2020 and has an exclusive technology of reactors and separators for the conversion of different feedstocks into hydrogen, among which are ammonia, methanol, or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration for applications in salt caverns or geologic hydrogen.

About Lloyd’s Register

Trusted maritime advisers, partnering with clients to drive performance across the ocean economy. Lloyd’s Register (LR) is a global professional services group specialising in marine engineering and technology. With a heritage going back more than 260 years to the establishment of the world’s first marine classification society, LR is dedicated to setting and improving standards for the safety of ships.

Today we are a leading provider of classification and compliance services to the marine and offshore industries, helping our clients design, construct and operate their assets to accepted levels of safety and environmental compliance. We also provide advice, support and solutions on fleet performance, fleet optimisation and voyage optimisation, enhancing our clients’ digital capabilities. Our digital solutions are relied upon by more than 20,000 vessels.

In the race to zero emissions, our research, technical expertise and industry-firsts are supporting a safe, sustainable maritime energy transition.

Lloyd’s Register Group is wholly owned by the Lloyd’s Register Foundation, a politically and financially independent global charity that promotes safety and education.

Find out more lr.org

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240428422597/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye